# Repligen Corporation – Consensus ‘buy’ rating and 38.5% Upside Potential

- Link: https://www.directorstalkinterviews.com/repligen-corporation-consensus-buy-rating-and-38.5-upside-potential/4121130148
- Published: 2023-10-20T13:07:54+01:00
- Author: Charlotte Edwards

**Repligen Corporation** which can be found using ticker (RGEN) now have 13 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
target price High/Low ranges between 240 and 165 suggesting an average Analsyt target
price of $197.31. Now with the previous closing price of $142.51 this would indicate
that there is a potential upside of 38.5%. The 50 day moving average now sits at
$161.60 and the 200 day MA is $166.34. The company has a market capitalization of
8.16B. The current share price for the company is: 146.28 USD

 The potential market cap would be $11,292,306,315 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/
E ratio of 60.7, revenue per share of 13.12 and a 3.46% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes
bioprocessing technologies and systems that rises flexibility in the process of 
manufacturing biological drugs. The Company’s bioprocessing business consist of 
four franchises, filtration; chromatography; process analytics; and proteins. The
Filtration products are used in process development and process scale production.
The Chromatography franchise includes products used in downstream purification, 
development, and manufacturing of biological drugs. The Process Analytics products
allow end-users to make in-line absorbance measurements allowing for the determination
of protein concentration in filtration, chromatography formulation and fill-finish
applications. The Proteins franchise is represented by its Protein A affinity ligands,
which are a critical component of Protein A chromatography resins used in downstream
purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on: